ALPN - Alpine Immune Sciences, Inc.
| Previous Close | 2.5700 |
| Open | 3.0000 |
| Bid | 2.1100 x 1100 |
| Ask | 0.0000 x 900 |
| Day's Range | 2.6000 - 3.0000 |
| 52 Week Range | 2.0500 - 8.2440 |
| Volume | 27,006 |
| Avg. Volume | 20,140 |
| Market Cap | 53.533M |
| Beta (5Y Monthly) | 2.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7280 |
| Earnings Date | Mar 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.75 |
- Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.
- ACCESSWIRE
Alpine Immune Sciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...
- Business Wire
Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has made two orphan drug designations for ALPN-101, Alpine’s first-in-class selective dual T cell costimulation inhibitor, for the prevention and for the treatment of acute GVHD.
- Business Wire
Alpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time. The Company is taking precautionary measures in response to the evolving coronavirus (COVID-19) situation in the Seattle area.
- Business Wire
Alpine Immune Sciences to Present at Two Upcoming Healthcare Investor Conferences
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March.
- Simply Wall St.
Have Insiders Been Buying Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares This Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Insider Monkey
Is Alpine Immune Sciences, Inc. (ALPN) A Good Stock To Buy?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]
- Benzinga
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
- Simply Wall St.
Do Institutions Own Shares In Alpine Immune Sciences, Inc. (NASDAQ:ALPN)?
Every investor in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) should be aware of the most powerful shareholder groups...
- Simply Wall St.
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Zacks
Analysts Estimate Alpine Immune Sciences (ALPN) to Report a Decline in Earnings: What to Look Out for
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Introducing Alpine Immune Sciences (NASDAQ:ALPN), The Stock That Dropped 43% In The Last Year
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...
